← All trials
NCT03992469
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2019
- Primary completion
- Jul 31, 2021
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.